Silver Oak Advisory Group Inc. Sells 42 Shares of Eli Lilly and Company (NYSE:LLY)

Silver Oak Advisory Group Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 715 shares of the company’s stock after selling 42 shares during the period. Silver Oak Advisory Group Inc.’s holdings in Eli Lilly and Company were worth $417,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of LLY. International Assets Investment Management LLC grew its position in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Sapient Capital LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at $435,736,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after buying an additional 645,473 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on LLY shares. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Truist Financial reissued a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Down 1.0 %

Eli Lilly and Company stock traded down $7.33 during midday trading on Thursday, hitting $724.87. 2,597,583 shares of the stock were exchanged, compared to its average volume of 3,034,002. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $370.68 and a 52 week high of $800.78. The company has a fifty day simple moving average of $762.75 and a two-hundred day simple moving average of $664.94. The stock has a market capitalization of $688.74 billion, a PE ratio of 124.98, a P/E/G ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the company earned $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.